FDA Study Halted After Jane Goodall Objects

The primatologist had written to the agency that the trial, which involved observing the effects of nicotine addiction in squirrel monkeys, was “cruel and unnecessary.”

Sep 26, 2017
Bob Grant

WIKIMEDIA, BORIS23The US Food and Drug Administration (FDA) has paused a study of nicotine addiction in squirrel monkeys that primatologist Jane Goodall objected to. She wrote a letter—in which she called the research “horrific”—to FDA Commissioner Scott Gottlieb. Although Gottlieb communicated with Goodall, an FDA spokesman tells The Scientist that the agency's decision to stop the study was independent of her plea. The letter from Goodall, an outspoken animal rights advocate, was posted on the website of the White Coat Waste (WCW) Project, an organization that seeks to stop animal research funded by US taxpayers, earlier this month (September 7).

According to the Washington Post, Gottlieb responded to Goodall on Monday (September 25), saying that he would temporarily suspend the three-year-old study, which FDA researchers are conducting at the agency’s National Center for Toxicological Research in Arkansas. The FDA commissioner reportedly assured Goodall that he made the decision “after learning of concerns related to the study you referenced,” and said that he was dispatching primate experts to the Arkansas facility “to evaluate the safety and well-being of the monkeys and to understand whether there are additional precautions needed.”

In her letter, Goodall took issue with the fact that juvenile monkeys were being implanted with devices that delivered nicotine directly into their systems and then taught to press a lever that dosed them with the drug. She also claimed that the animals were isolated in cages for “nearly three years,” and referenced video footage that exists documenting the conditions. “To continue performing nicotine experiments on monkeys when the results of smoking are well-known in humans—whose smoking habits can still be studied directly—is shameful,” Goodall wrote. “I’m sure that most Americans would be horrified to learn their tax dollars are paying for this abuse.”

The WCW apparently asked Goodall to write the letter after obtaining information about the research, which involved 12 adult and 12 adolescent monkeys, via the Freedom of Information Act.

While the WCW applauded the FDA’s decision to halt the trial, others in the scientific community expressed their displeasure with Goodall’s assertions. An editor writing last week (September 20) on Speaking of Research, a website for an animal research advocacy group, decries Goodall’s lack of “relevant credentials,” her propagation of “factual inaccuracies” in her letter describing the squirrel monkey research, and her “sweeping assumptions.”

“Studies such as those conducted by the FDA in animals, including monkeys, will teach us how these new delivery methods affect the brain and body, which will in turn lead to recommendations for regulation of these products and potential treatments for addiction,” the editor writes. “Despite these life-saving benefits, Goodall and WCW call for an end to this line of research in their letter.”

Correction (September 27): We have updated the first paragraph to indicate that Goodall’s letter did not influence Gottlieb’s decision to stop the study. The Scientist regrets the error.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets


Sponsored Product Updates

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!